Scott M. Wasserman

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Heart Failure, Lipid Peroxidation, Hyperlipidemia +19

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung, Andreas Grauer, Steven Boonen et al. · New England Journal of Medicine · 2014 · 1.2K citations

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

Stephen J. Nicholls, Rishi Puri, Todd J. Anderson et al. · JAMA · 2016 · 1.1K citations · Full text

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 895 citations · Full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11